Diffuse large B-cell lymphoma: to maintain or not?
Mené sur 46 patients atteints d'un lymphome diffus à grandes cellules B récidivant après une greffe autologue de cellules souches ou non éligibles pour la greffe, cet essai de phase II évalue l'efficacité, du point de vue de la survie sans progression à un an, et la toxicité du lénalidomide en traitement d'entretien
Patients with diffuse large B-cell lymphoma (DLBCL) who are responding to treatment can be given a drug to maintain this response, or even further the response to delay relapse. The effect of this maintenance treatment has been reported in acute lymphoblastic leukaemia, and more recently, in follicular lymphomas and mantle cell, lymphomas.1,2 In the Lancet Haematology, Andres J M Ferreri and colleagues3 present results from a phase 2 trial of lenalidomide maintenance in patients with DLBCL who have relapsed, are not eligible for transplant, and responded to first or second salvage therapy.
The Lancet Hematology , commentaire, 2016